At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Systemic Sclerosis
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Aug 23, 2021·Updated Apr 8, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Systemic Sclerosis. Currently recruiting, targeting 20 participants across 2 sites in 2 countries.
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Sclerosis
CountriesAntigua and Barbuda, Argentina
Collaborators--
Timeline
Phase 1Recruiting
20222023202420252026
First PostedAug 2021
Enrollment StartJul 2022
TodayJul 2026
Primary CompletionNov 2026
First PostedAug 23, 2021
Enrollment StartJul 4, 2022
Primary CompletionNov 1, 2026
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 4.9 years agoPrimary completion in 4 months
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells